



## Spinal Cord Injury and Repair: Drug Targets and Treatments

Guest Editor:

**Dr. Meng-Jen Lee**

Department of Applied  
Chemistry, Chaoyang University  
of Technology, Taichung 413310,  
Taiwan

Deadline for manuscript  
submissions:

**closed (30 June 2023)**

### Message from the Guest Editor

Spinal cord injury (SCI) has been a major cause of patient suffering and financial burden. The identification of drug targets for spinal cord injury and means to act on these targets have greatly accelerated progress towards functional recovery after trauma. Efforts have been directed towards the molecular characterization of spinal cord injury drug targets using many in vitro and in vivo injury models. High-throughput methods as well as structure-sensitive studies have significantly expanded the repertoire of potential targets. This Special Issue of *Biomedicines* focuses on recent advances in the characterization, translation, and clinical application of spinal cord injury treatment targets as well as agents that act on the targets. The goal is to encourage research and clinical strategies which, to date, are still less than satisfactory, in the hope to improve the quality of life of SCI patients.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)